Adverse effects of antiepileptic drugs

The Lancet Neurology

Volumn 11, Issue 9, 2012, Pages 792-802

  Perucca, Piero ^a   Gilliam, Frank G ^b  

^a MCGILL UNIVERSITY   (Canada)

^b GEISINGER HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ESLICARBAZEPINE ACETATE; ETIRACETAM; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; PRIMIDONE; RETIGABINE; TIAGABINE; TOPIRAMATE; ZONISAMIDE;

ADVERSE OUTCOME; AGRANULOCYTOSIS; ALOPECIA; APLASTIC ANEMIA; ASEPTIC MENINGITIS; ATAXIA; BIRTH DEFECT; BONE DENSITY; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; CONNECTIVE TISSUE DISEASE; COORDINATION DISORDER; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG TOLERABILITY; EPILEPSY; FATIGUE; FOLIC ACID DEFICIENCY; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPONATREMIA; INSOMNIA; LETHARGY; LIVER TOXICITY; NYSTAGMUS; PANCREATITIS; PARESTHESIA; PRIORITY JOURNAL; PSEUDOLYMPHOMA; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; TREATMENT FAILURE; TREMOR; UNSTEADINESS; VERTIGO; VISUAL FIELD DEFECT; WEIGHT GAIN; WEIGHT REDUCTION;

AGE FACTORS; ANTICONVULSANTS; EPILEPSY; HUMANS;

EID: 84865115095     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70153-9     Document Type: Review

References (100)

1. Kwan P, Brodie MJ Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-319.
2. Perucca P, Carter J, Vahle V, Gilliam FG Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology 2009, 72:1223-1229.
3. Gilliam F, Carter J, Vahle V Tolerability of antiseizure medications: implications for health outcomes. Neurology 2004, 63(suppl 4):S9-12.
4. Suh DC, Woodall BS, Shin SK, Hermes-De Santis ER Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 2000, 34:1373-1379.
5. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985, 313:145-151.
6. International drug monitoring: the role of national centres. World Health Organ Tech Rep Ser 1972, 498:1-25. World Health Organization.
7. Edwards IR, Aronson JK Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000, 356:1255-1259.
8. Baker GA, Camfield C, Camfield P, et al. Commission on Outcome Measurement in Epilepsy, 1994-1997: final report. Epilepsia 1998, 39:213-231.
9. Carreno M, Gil-Nagel A, Sanchez JC, et al. Strategies to detect adverse effects of antiepileptic drugs in clinical practice. Epilepsy Behav 2008, 13:178-183.
10. Canevini MP, De Sarro G, Galimberti CA, et al. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia 2010, 51:797-804.
11. Adverse reactions to antiepileptic drugs: a multicenter survey of clinical practice. Epilepsia 1986, 27:323-330. Collaborative Group for Epidemiology of Epilepsy.
12. Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D Quality of life of people with epilepsy: a European study. Epilepsia 1997, 38:353-362.
13. Carpay HA, Arts WF, Vermeulen J, et al. Parent-completed scales for measuring seizure severity and severity of side-effects of antiepileptic drugs in childhood epilepsy: development and psychometric analysis. Epilepsy Res 1996, 24:173-181.
14. Morita DA, Glauser TA, Altaye M, Fordyce SR, Holder DL The Cincinnati AED Side-Effect Scale (CASE Scale): development and validation of a tool to measure antiepileptic drug side effects objectively in children with epilepsy. Epilepsia 2003, 44(suppl 9):279.
15. Cramer JA, Smith DB, Mattson RH, Delgado Escueta AV, Collins JF A method of quantification for the evaluation of antiepileptic drug therapy. Neurology 1983, 33(suppl 1):26-37.
16. Baker GA, Frances P, Middleton E, et al. Initial development, reliability, and validity of a patient-based adverse events scale. Epilepsia 1994, 35(suppl 7):80.
17. Aldenkamp AP, Baker G, Pieters MS, Schoemaker HC, Cohen AF, Schwabe S The Neurotoxicity Scale: the validity of a patient-based scale, assessing neurotoxicity. Epilepsy Res 1995, 20:229-239.
18. Salinsky MC, Storzbach D The Portland Neurotoxicity Scale: validation of a brief self-report measure of antiepileptic-drug-related neurotoxicity. Assessment 2005, 12:107-117.
19. Uijl SG, Uiterwaal CS, Aldenkamp AP, et al. A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs. Seizure 2006, 15:242-248.
20. Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 2004, 62:23-27.
21. Kwon OY, Park SP What is the role of depressive symptoms among other predictors of quality of life in people with well-controlled epilepsy on monotherapy?. Epilepsy Behav 2011, 20:528-532.
22. Carreno M, Donaire A, Falip M, et al. Validation of the Spanish version of the Liverpool Adverse Events Profile in patients with epilepsy. Epilepsy Behav 2009, 15:154-159.
23. Yue L, Yu PM, Zhao DH, et al. Determinants of quality of life in people with epilepsy and their gender differences. Epilepsy Behav 2011, 22:692-696.
24. Martins HH, Alonso NB, Vidal-Dourado M, et al. Are adverse effects of antiepileptic drugs different in symptomatic partial and idiopathic generalized epilepsies? The Portuguese-Brazilian validation of the Liverpool Adverse Events Profile. Epilepsy Behav 2011, 22:511-517.
25. Chen HF, Tsai YF, Shih MS, Chen JC Validation of the Chinese version of the Liverpool Adverse Events Profile in patients with epilepsy. Epilepsy Res 2011, 94:45-52.
26. Luoni C, Bisulli F, Canevini MP, et al. Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia 2011, 52:2181-2191.
27. Perucca E, Kwan P Overtreatment in epilepsy: how it occurs and how it can be avoided. CNS Drugs 2005, 19:897-908.
28. Perucca P, Jacoby A, Marson AG, et al. Adverse antiepileptic drug effects in new-onset seizures: a case-control study. Neurology 2011, 76:273-279.
29. Perucca E, Meador KJ Adverse effects of antiepileptic drugs. Acta Neurol Scand Suppl 2005, 181:30-35.
30. Kennedy GM, Lhatoo SD CNS adverse events associated with antiepileptic drugs. CNS Drugs 2008, 22:739-760.
31. Sirven JI, Fife TD, Wingerchuk DM, Drazkowski JF Second-generation antiepileptic drugs' impact on balance: a meta-analysis. Mayo Clin Proc 2007, 82:40-47.
32. Fattore C, Perucca E Novel medications for epilepsy. Drugs 2011, 71:2151-2178.
33. Kwan P, Brodie MJ Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 2001, 357:216-222.
34. Loring DW, Marino S, Meador KJ Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol Rev 2007, 17:413-425.
35. Weintraub D, Buchsbaum R, Resor SR, Hirsch LJ Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2007, 10:105-110.
36. Schmitz B Effects of antiepileptic drugs on mood and behavior. Epilepsia 2006, 47(suppl 2):28-33.
37. Joint meeting of the Peripheral and Central Nervous Drugs Advisory Committee and the Psychopharmacologic Drugs Advisory Committee: briefing material US Food and Drug Administration, (accessed Feb 20, 2012). http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-00-index.html.
38. Mula M, Trimble MR, Lhatoo SD, Sander JW Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003, 44:659-663.
39. Mula M, Trimble MR, Yuen A, Liu RS, Sander JW Psychiatric adverse events during levetiracetam therapy. Neurology 2003, 61:704-706.
40. White JR, Walczak TS, Marino SE, Beniak TE, Leppik IE, Birnbaum AK Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. Neurology 2010, 75:513-518.
41. Franciotta D, Kwan P, Perucca E Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol 2009, 22:144-149.
42. Zaccara G, Franciotta D, Perucca E Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007, 48:1223-1244.
43. Chadwick D, Shaw MD, Foy P, Rawlins MD, Turnbull DM Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. J Neurol Neurosurg Psychiatry 1984, 47:642-644.
44. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005, 64:1134-1138.
45. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004, 428:486.
46. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011, 364:1126-1133.
47. Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007, 48:1015-1018.
48. Chen YC, Chu CY, Hsiao CH Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. J Eur Acad Dermatol Venereol 2009, 23:702-703.
49. Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011, 20:1034-1041.
50. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011, 364:1134-1143.
51. Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997, 38:1265-1269.
52. Pellock JM, Faught E, Leppik IE, Shinnar S, Zupanc ML Felbamate: consensus of current clinical experience. Epilepsy Res 2006, 71:89-101.
53. Handoko KB, Souverein PC, van Staa TP, et al. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia 2006, 47:1232-1236.
54. Ibanez L, Vidal X, Ballarin E, Laporte JR Population-based drug-induced agranulocytosis. Arch Intern Med 2005, 165:869-874.
55. Andres E, Maloisel F Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol 2008, 15:15-21.
56. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004, 10:1018-1023.
57. Bjornsson E Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand 2008, 118:281-290.
58. Gerstner T, Busing D, Bell N, et al. Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol 2007, 42:39-48.
59. Cramer JA, Mintzer S, Wheless J, Mattson RH Adverse effects of antiepileptic drugs: a brief overview of important issues. Expert Rev Neurother 2010, 10:885-891.
60. Jallon P, Picard F Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001, 24:969-978.
61. Biton V Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003, 17:781-791.
62. Mintzer S, Skidmore CT, Abidin CJ, et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 2009, 65:448-456.
63. Mintzer S Metabolic consequences of antiepileptic drugs. Curr Opin Neurol 2010, 23:164-169.
64. Souverein PC, Webb DJ, Weil JG, Van Staa TP, Egberts AC Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 2006, 66:1318-1324.
65. Pack AM Treatment of epilepsy to optimize bone health. Curr Treat Options Neurol 2011, 13:346-354.
66. Plant GT, Sergott RC Understanding and interpreting vision safety issues with vigabatrin therapy. Acta Neurol Scand Suppl 2011, 192:57-71.
67. Hardus P, Verduin WM, Postma G, Stilma JS, Berendschot TT, van Veelen CW Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia 2000, 41:581-587.
68. Wild JM, Ahn HS, Baulac M, et al. Vigabatrin and epilepsy: lessons learned. Epilepsia 2007, 48:1318-1327.
69. Maguire MJ, Hemming K, Wild JM, Hutton JL, Marson AG Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia 2010, 51:2423-2431.
70. Tomson T, Battino D The management of epilepsy in pregnancy. The blue books of neurology: the epilepsies 3 2009, 241-264. Saunders Elsevier, Philadelphia. S. Shorvon, T.A. Pedley (Eds.).
71. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006, 77:193-198.
72. Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009, 73:133-141.
73. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011, 10:609-617. for the EURAP study group.
74. Hernández-Díaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012, 78:1692-1699.
75. Meador KJ, Baker GA, Browning N, et al. Effects of fetal antiepileptic drug exposure: outcomes at age 4·5 years. Neurology 2012, 78:1207-1214.
76. Bromley RL, Mawer G, Love J, et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia 2010, 51:2058-2065.
77. Palac S, Meador KJ Antiepileptic drugs and neurodevelopment: an update. Curr Neurol Neurosci Rep 2011, 11:423-427.
78. Singh G, Driever PH, Sander JW Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 2005, 128:7-17.
79. Jeng YM, Tien HF, Su IJ Phenytoin-induced pseudolymphoma: reevaluation using modern molecular biology techniques. Epilepsia 1996, 37:104-107.
80. Choi TS, Doh KS, Kim SH, Jang MS, Suh KS, Kim ST Clinicopathological and genotypic aspects of anticonvulsant-induced pseudolymphoma syndrome. Br J Dermatol 2003, 148:730-736.
81. Patsalos PN, Perucca E Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003, 2:473-481.
82. Patsalos PN, Perucca E Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003, 2:347-356.
83. Perucca E Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006, 61:246-255.
84. Kanner AM, Frey M Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 2000, 55:588-591.
85. Crawford P Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002, 16:263-272.
86. Baruzzi A, Albani F, Riva R Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994, 35(suppl 3):S14-S19.
87. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999, 40:985-991.
88. Brodie MJ, Overstall PW, Giorgi L Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 1999, 37:81-87. for The UK Lamotrigine Elderly Study Group.
89. Brodtkorb E Management of epilepsy in people with learning disabilities. The treatment of epilepsy 2009, 219-230. Wiley-Blackwell, Oxford. 3rd edn. S. Shorvon, E. Perucca, J. Engel (Eds.).
90. Sidhu J, Job S, Singh S, Philipson R The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 2006, 61:191-199.
91. Definition of health World Health Organization, (accessed June 22, 2012). http://www.who.int/about/definition/en/print.html.
92. Sillanpaa M, Haataja L, Shinnar S Perceived impact of childhood-onset epilepsy on quality of life as an adult. Epilepsia 2004, 45:971-977.
93. Gilliam F Optimizing health outcomes in active epilepsy. Neurology 2002, 58(suppl 5):S9-20.
94. Uijl SG, Uiterwaal CS, Aldenkamp AP, et al. Adjustment of treatment increases quality of life in patients with epilepsy: a randomized controlled pragmatic trial. Eur J Neurol 2009, 16:1173-1177.
95. Zaccara G, Balestrieri F, Ragazzoni A Management of side-effects of antiepileptic drugs. The treatment of epilepsy 2009, 289-300. Wiley-Blackwell, Oxford. 3rd edn. S. Shorvon, E. Perucca, J. Engel (Eds.).
96. Messenheimer J, Mullens EL, Giorgi L, Young F Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998, 18:281-296.
97. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs: best practice guidelines for therapeutic drug monitoring-a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008, 49:1239-1276.
98. Ruble J, Matsuo H Anticonvulsant-induced cutaneous reactions: incidence, mechanism and management. CNS Drugs 1999, 12:215-236.
99. Hirsch LJ, Weintraub DB, Buchsbaum R, et al. Predictors of lamotrigine-associated rash. Epilepsia 2006, 47:318-322.
100. Simms KM, Kortepeter C, Avigan M Lamotrigine and aseptic meningitis. Neurology 2012, 78:921-927.